There are 350 million positives with Hepatitis B viruses (HBV) globally, and more than one million people die annually from Hepatitis B or its associated diseases. In China , there are 120 million positives with HBV.
The drug design is based on:
Proprietary Structure-based Drug Design
Experience in the study of creatine kinase analogue and its substrate
Comparison of 3D structures between HIV reverse transcriptase and HBV
polymerase
The advantages:
Good oral availability and high efficacy in
comparison to Lamivudine
There are 350 million positives with Hepatitis B viruses (HBV) globally, and more than one million people die annually from Hepatitis B or its associated diseases. In China , there are 120 million positives with HBV.
